52 In a phase 1b trial done to evaluate the safety, pharmacokinetics and pharmacodynamics of orforglipron in patients with T2DM, orforglipron resulted in significant reductions in HbA1c, fasting blood glucose and body weight, with an adverse event profile consistent with that of other GLP-1RA
But beneath the glossy packaging, influencer reviews, and scientific-looking graphics, the story quickly unravels
While GLP-1 agonists offer a powerful option for those struggling with obesity or metabolic conditions, traditional approaches remain a viable solution for many
Coskun T, The Lancet (Vol
Structural and molecular conservation of glucagon-like Peptide-1 and its receptor confers selective ligand-receptor interaction
First developed as anti-diabetes medications, in the pancreas these drugs stimulate production of insulin, the hormone that helps reduce blood glucose levels after a meal